BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 27899083)

  • 1. Tumor characteristics and prognosis in familial breast cancer.
    Arpino G; Pensabene M; Condello C; Ruocco R; Cerillo I; Lauria R; Forestieri V; Giuliano M; De Angelis C; Montella M; Crispo A; De Placido S
    BMC Cancer; 2016 Nov; 16(1):924. PubMed ID: 27899083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer.
    Gonzalez-Angulo AM; Timms KM; Liu S; Chen H; Litton JK; Potter J; Lanchbury JS; Stemke-Hale K; Hennessy BT; Arun BK; Hortobagyi GN; Do KA; Mills GB; Meric-Bernstam F
    Clin Cancer Res; 2011 Mar; 17(5):1082-9. PubMed ID: 21233401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study.
    Musolino A; Bella MA; Bortesi B; Michiara M; Naldi N; Zanelli P; Capelletti M; Pezzuolo D; Camisa R; Savi M; Neri TM; Ardizzoni A
    Breast; 2007 Jun; 16(3):280-92. PubMed ID: 17257844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcome and global gene expression data support the existence of the estrogen receptor-negative/progesterone receptor-positive invasive breast cancer phenotype.
    Schroth W; Winter S; Büttner F; Goletz S; Faißt S; Brinkmann F; Saladores P; Heidemann E; Ott G; Gerteis A; Alscher MD; Dippon J; Schwab M; Brauch H; Fritz P
    Breast Cancer Res Treat; 2016 Jan; 155(1):85-97. PubMed ID: 26650824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations.
    Robson M; Levin D; Federici M; Satagopan J; Bogolminy F; Heerdt A; Borgen P; McCormick B; Hudis C; Norton L; Boyd J; Offit K
    J Natl Cancer Inst; 1999 Dec; 91(24):2112-7. PubMed ID: 10601383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Familial breast cancer: characteristics and outcome of BRCA 1-2 positive and negative cases.
    Veronesi A; de Giacomi C; Magri MD; Lombardi D; Zanetti M; Scuderi C; Dolcetti R; Viel A; Crivellari D; Bidoli E; Boiocchi M
    BMC Cancer; 2005 Jul; 5():70. PubMed ID: 15996267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Significance of Single Progesterone Receptor Positivity: A Comparison Study of Estrogen Receptor Negative/Progesterone Receptor Positive/Her2 Negative Primary Breast Cancer With Triple Negative Breast Cancer.
    Fan Y; Ding X; Xu B; Ma F; Yuan P; Wang J; Zhang P; Li Q; Luo Y
    Medicine (Baltimore); 2015 Nov; 94(46):e2066. PubMed ID: 26579819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Characteristics and Outcomes of Single Versus Double Hormone Receptor-Positive Breast Cancer in 2 Large Databases.
    Li Z; Tu Y; Wu Q; Wang Z; Li J; Zhang Y; Sun S
    Clin Breast Cancer; 2020 Apr; 20(2):e151-e163. PubMed ID: 31551181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study.
    Copson ER; Maishman TC; Tapper WJ; Cutress RI; Greville-Heygate S; Altman DG; Eccles B; Gerty S; Durcan LT; Jones L; Evans DG; Thompson AM; Pharoah P; Easton DF; Dunning AM; Hanby A; Lakhani S; Eeles R; Gilbert FJ; Hamed H; Hodgson S; Simmonds P; Stanton L; Eccles DM
    Lancet Oncol; 2018 Feb; 19(2):169-180. PubMed ID: 29337092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of triple negative phenotype on breast cancer prognosis.
    Kaplan HG; Malmgren JA
    Breast J; 2008; 14(5):456-63. PubMed ID: 18657139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
    Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
    BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of nodal metastasis between BRCA mutation carriers and non-BRCA mutation carriers with breast cancer.
    Noori SF; Gangi A; Nelson ME; Choi M; Mirzadehgan P; Bonk AK; Mirocha J; Amersi F; Giuliano AE
    Ann Surg Oncol; 2014 Oct; 21(10):3324-9. PubMed ID: 25047471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population.
    Reiner AS; Lynch CF; Sisti JS; John EM; Brooks JD; Bernstein L; Knight JA; Hsu L; Concannon P; Mellemkjær L; Tischkowitz M; Haile RW; Shen R; Malone KE; Woods M; Liang X; Morrow M; Bernstein JL;
    Breast Cancer Res; 2017 Jul; 19(1):83. PubMed ID: 28724391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognosis of BRCA1/2-negative breast cancer patients with HBOC risk factors compared with sporadic breast cancer patients without HBOC risk factors.
    Ryu JM; Nam SJ; Kim SW; Lee JE; Chae BJ; Lee SK; Yu J
    Jpn J Clin Oncol; 2020 Feb; 50(2):104-113. PubMed ID: 31926487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of BRCA germline mutations on breast cancer prognosis: A systematic review and meta-analysis.
    Baretta Z; Mocellin S; Goldin E; Olopade OI; Huo D
    Medicine (Baltimore); 2016 Oct; 95(40):e4975. PubMed ID: 27749552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRCA-associated breast cancer in young women.
    Robson M; Gilewski T; Haas B; Levin D; Borgen P; Rajan P; Hirschaut Y; Pressman P; Rosen PP; Lesser ML; Norton L; Offit K
    J Clin Oncol; 1998 May; 16(5):1642-9. PubMed ID: 9586873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: Differences based on germline mutation status.
    Shah PD; Patil S; Dickler MN; Offit K; Hudis CA; Robson ME
    Cancer; 2016 Apr; 122(8):1178-84. PubMed ID: 26859126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Factors for Luminal B-like Breast Cancer.
    Ding NH; Liu CF; Hu C; Yuan JQ; Liao WH; Xiao Z
    Curr Med Sci; 2019 Jun; 39(3):396-402. PubMed ID: 31209809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Limited family structure and triple-negative breast cancer (TNBC) subtype as predictors of BRCA mutations in a genetic counseling cohort of early-onset sporadic breast cancers.
    Zugazagoitia J; Pérez-Segura P; Manzano A; Blanco I; Vega A; Custodio A; Teulé A; Fachal L; Martínez B; González-Sarmiento R; Cruz-Hernández JJ; Chirivella I; Garcés V; Garre P; Romero A; Caldés T; Díaz-Rubio E; de la Hoya M
    Breast Cancer Res Treat; 2014 Nov; 148(2):415-21. PubMed ID: 25342642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction between Hormonal Receptor Status, Age and Survival in Patients with BRCA1/2 Germline Mutations: A Systematic Review and Meta-Regression.
    Templeton AJ; Gonzalez LD; Vera-Badillo FE; Tibau A; Goldstein R; Šeruga B; Srikanthan A; Pandiella A; Amir E; Ocana A
    PLoS One; 2016; 11(5):e0154789. PubMed ID: 27149669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.